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Evidence for the effectiveness of prenatal or postnatal treatment for congenital toxoplasmosis will be critical 
to guide policy about prenatal and neonatal screening over the next 10 years, let alone the next 100. Randomised 
controlled trials are needed to address questions about treatment effectiveness, although cohort studies are also 
needed to provide information on prognosis, especially disability. Nowhere are such studies needed more than in 
South America where congenital toxoplasmosis is a major public health problem. 
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Does treatment work? This is the central question that 
continues to trouble clinicians caring for mothers exposed 
to toxoplasmosis during pregnancy and their children. 
After more than a decade of international collaborative 
studies to address this question, we still do not have a 
clear answer. The imperative for the next 100 years, or 
even the next 10 years, is to answer this question. 
The need for an answer is particularly urgent for pre-
natal treatment. At the moment, we do not know whether 
women and their babies are more likely to be helped than 
harmed when we offer prenatal screening. The clinical 
and ethical dilemmas are well known. Congenital toxo-
plasmosis only occurs when the mother acquires infection 
during pregnancy. The only way to reliably identify infect-
ed women is through serological screening, as few women 
have symptoms of infection and few infected fetuses show 
abnormal signs that might be detected by routine fetal ul-
trasound. This means that to find women who acquired 
toxoplasmic infection during pregnancy, we have to offer 
repeated screening tests to all pregnant women. 
Ethically, we can only justify doing this if we can 
offer an intervention that will, on average, improve out-
comes for the women who take up screening. The ben-
efits need to be clear and measurable as the downsides 
are considerable (Gilbert and Peckham 2002). A positive 
test result turns a healthy pregnant woman into a woman 
who acquired an infection that she could have avoided, 
might blind her fetus and cause brain damage, and com-
mits her to repeated testing, invasive fetal diagnosis and 
antibiotic treatment throughout pregnancy and her child 
to  tests  and  treatment  throughout  infancy.  She  could 
consider the alternative intervention of pregnancy ter-
mination, but with rare exceptions, this is not generally 
acceptable as so many unaffected fetuses have to be ter-
minated unnecessarily for every affected fetus (Berrebi 
et al. 1994, 2007, Bader et al. 1997, Thalib et al. 2005). 
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The ethical imperative to demonstrate that benefits 
outweigh harms before implementing a screening pro-
gramme has been echoed by numerous policy bodies 
(UK National Screening Committee 2003, Potter et al. 
2008). These principles apply equally to neonatal screen-
ing for congenital toxoplasmosis, although there is even 
less evidence that postnatal treatment works than prena-
tal treatment. On the other hand, the harms and benefits 
are less finely balanced, as the harms associated with 
neonatal screening are fewer and less serious than for 
prenatal screening (Gilbert et al. 2006, Freeman et al. 
2008, Potter et al. 2008). In this paper, I focus on the 
challenges to finding out whether treatment works, what 
we know already, and what researchers need to find out 
to make our practice more effective. 
Challenges 
Congenital toxoplasmosis poses several methodolo-
gical  challenges.  In  part,  these  explain  why  we  still 
know  so  little  about  treatment  effectiveness.  Firstly, 
because infection during pregnancy can only be identi-
fied by screening, studies of treatment effectiveness can 
only be conducted in centres where prenatal screening 
is offered to all women. France, Austria and Italy pro-
vide universal screening, as do certain centres in Spain, 
Switzerland and Belgium (SYROCOT Study Group et 
al. 2007, Benard et al. 2008). Outside Europe, prenatal 
screening is often confined to the private sector (Neto 
et al. 2000, Segundo et al. 2004, Gilbert et al. 2008). 
Secondly, very large numbers of pregnant women need 
to be studied. This is partly because the incidence of in-
fection during pregnancy is low, between 1-8 per 1,000 
susceptible pregnancies, with the highest rates reported 
in France (Gilbert & Peckham 2002). A further reason is 
the outcomes that are clinically important are rare. About 
one-third of infected women give birth to an infected fe-
tus, but only 5% have serious neurological sequelae that 
would be apparent in the first two years of life (this is 
about 1.6% of infected pregnancies) (Gras et al. 2005, 
SYROCOT Study Group 2007). Thirdly, infected chil-
dren need long term follow up to determine the impact 
of congenital toxoplasmosis on impairment or disability. 
By adolescence, about 30% of infected children have 
retinochoroiditis, but only 9% of these (2.7% of infected Does treatment work? • Ruth Gilbert 306
children and 0.9% of infected pregnancies) develop bi-
lateral visual impairment severe enough to affect eligi-
bility for a driving license (Wallon et al. 2004, Tan et al. 
2007, Freeman et al. 2008). These are average figures 
for children born to treated and untreated mothers, but 
they illustrate that any reduction in risk associated with 
treatment is likely to be small. 
A fourth challenge is the confounding effect of tim-
ing of maternal infection. Timing of infection is strongly 
linked to the risks of fetal infection and of brain lesions 
and neurological impairment. It is also linked to whether 
and when the woman is treated (Gilbert et al. 2003, Gras 
et al. 2005, Thiebaut et al. 2006, SYROCOT Study Group 
2007). Given a monthly re-testing schedule for suscepti-
ble women, those infected early in the first trimester have 
a longer delay before treatment than women infected in 
the 2nd or 3rd trimesters, and women infected late in the 
3rd trimester are less likely to be treated at all (Gilbert et 
al. 2003). A further problem is the difficulty of accurately 
measuring timing of infection (Thiebaut et al. 2006). Cur-
rently the best measure is detection of seroconversion. We 
do not know when seroconversion occurs exactly, only 
the interval between the last negative and first positive 
serological test. Increasingly, research studies are using 
special statistical methods to take into account the uncer-
tainty of the timing of seroconversion (Gras et al. 2005, 
Thiebaut  et  al.  2006,  SYROCOT  Study  Group  2007). 
Confounding is a particular problem for cohort studies 
which is minimised by randomised controlled trials. 
The fifth challenge relates to the biology of the para-
site. Toxoplasma gondii has a short ‘therapeutic window’ 
when treatment can act on tachyzoites. This ‘window’ is 
limited by the duration of maternal parasitaemia, which 
probably ceases with the development of the maternal 
serological response. Once parasites have entered the fe-
tal circulation, the therapeutic window depends on how 
rapidly the fetal immune response drives the tachyzoite 
into the encysted, dormant bradyzoite form, which is im-
penetrable to antibiotics (Denkers et al. 1998). As fetal 
immunity matures, we would expect a shorter ‘window’ 
of tachyzoite replication, but the timing of maturation 
may differ between individuals (Jamieson et al. 2008). 
One implication of these findings is that early timing 
of treatment after maternal seroconversion is likely to 
be critical (Gras et al. 2005, SYROCOT Study Group 
2007). Yet, as already outlined, measuring how soon 
treatment starts after maternal seroconversion is no easy 
task. A further implication of the need for early treat-
ment is that prenatal treatment is likely to have a big-
ger effect on clinical manifestations in infected children 
than postnatal treatment.
The last challenge threatens the generalisability of 
findings across populations. Evidence is emerging that 
the clinical course of congenital toxoplasmosis differs in 
Europe and North America compared with parts of South 
America (Gomez-Marin et al. 2007, Gilbert et al. 2008). 
Ocular disease is five times more common in children 
with  congenital  toxoplasmosis  identified  by  neonatal 
screening in Brazil than in children identified by prena-
tal or neonatal screening Europe. Moreover, lesions recur 
more frequently, are bigger and more likely to threaten 
vision (Gilbert et al. 2008). This is likely to be due to 
exposure to more virulent strains of T. gondii in Brazil. 
Type 1 and atypical strains appear to be associated with 
more severe ocular disease (Vallochi et al. 2005, Khan 
et al. 2006). compared with type II strains, which pre-
dominate in Europe and North America (Ajzenberg et al. 
2004, de Moura et al. 2006, Dubey et al. 2006, 2007, Le-
hmann et al. 2006, Nowakowska et al. 2006). These find-
ings suggest that treatment effectiveness in Europe and 
North America can not be extrapolated to settings where 
more virulent genotypes predominate. One reason is the 
absolute reduction in risk associated with treatment will 
be greater in settings where the baseline risk of adverse 
outcomes is higher. A second reason is that pharmaco-
dynamics may differ. Evidence of strain differences in 
parasite replication, penetration of host tissues, and the 
interaction between parasite and host immunity, is start-
ing to emerge (Saeij et al. 2006, 2007, Fux et al. 2007). 
So far, researchers have paid less attention to how these 
factors could affect the response to treatment and the need 
for early or continuing treatment. 
 
Prenatal treatment: what do we know already?
So far, our knowledge about the effectiveness of pre-
natal treatment has been based entirely on cohort stud-
ies. The results are summarised for different treatment 
questions and outcomes in the Table. The most robust 
evidence comes from a systematic review and individual 
patient data meta-analysis of 20 European cohort studies 
(1,438 women) in which universal screening for toxoplas-
mosis in pregnancy was performed (SYROCOT Study 
Group 2007). The analysis assessed the effect of timing 
and type of prenatal treatment on mother-to-child trans-
mission of infection and clinical manifestations before 
age one year. Prenatal treatment consisted of spiramycin 
alone or pyrimethamine-sulphonamides and spiramycin 
followed by pyrimethamine-sulphonamides. 
The systematic review found weak evidence that treat-
ment  started  within  three  weeks  of  seroconversion  re-
duced mother-to-child transmission compared with treat-
ment started after eight or more weeks (Odds ratio 0.48, 
95% CI 0.28-0.80; p = 0.05), but they could not distinguish 
whether this was a real benefit of treatment or a bias due 
to late detection and inclusion in the cohort of women at 
increased risk of fetal infection (SYROCOT Study Group 
2007).  Only one in five women were treated within three 
weeks of seroconversion, despite the fact that most (76%) 
were identified in France, where a regimen of monthly re-
testing is mandated by law. Thus, even if early treatment 
is effective, it may be difficult to identify and treat women 
sufficiently quickly after seroconversion. 
To date, no studies have found any evidence that ear-
ly prenatal treatment reduces the risk of retinochoroiditis 
during infancy (SYROCOT Study Group 2007). Simi-
larly, two large cohort studies that assessed the presence 
of retinochoroiditis in children up to school age found 
no evidence that prenatal treatment reduced the risk of 
lesions (Binquet et al. 2003, Freeman 2008). However, 
there is weak and inconsistent evidence that early pre-
natal treatment may have an impact on brain lesions in 
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review were not significant at the 5% level (Gras et al. 
2005, SYROCOT Study Group 2007). Whether this is 
a true effect, or due to selection bias from exclusion of 
fetuses of treated women who were terminated after de-
tection of intracranial lesions on fetal ultrasound is un-
certain. Work is in progress to determine whether pre-
natal treatment reduces the risk of serious neurological 
sequelae in the 5% of congenitally infected infants with 
these findings (RE Gilbert, personal communication, on 
behalf of the European Multicentre Study of Congenital 
Toxoplasmosis, EMSCOT). 
There  is  considerable  debate  about  which  type  of 
prenatal treatment is best. Over the last 15 years, cohort 
studies have consistently found no evidence that treat-
ment with a pyrimethamine-sulfonamide combination is 
more effective than spiramycin alone for reducing the risk 
of mother to child transmission of infection or clinical 
manifestations in the infected infant (Foulon et al. 1999, 
Gilbert et al. 2003, Gras et al. 2005, SYROCOT Study 
Group  2007,  Freeman  2008).  Randomised  controlled 
trials are needed to resolve which type of treatment is 
best. This is because selection bias is likely to affect who 
receives which type of treatment. Secondly, results so 
far indicate that, at best, any effect of pyrimethamine-
sulphonamide combinations over spiramycin is likely to 
be small. Randomised controlled trials are much better 
for quantifying effects than cohort studies because they 
minimize error due to confounding. 
Despite the lack of evidence for effectiveness, py-
rimethamine-sulphonamide  combinations  are  widely 
recommended, based on evidence that levels of spiramy-
cin in fetal blood samples are about half those found 
in maternal serum and may be insufficient for treating 
fetal infection (Forestier et al. 1987, Remington 2006). 
This reasoning is questionable, given the difficulty in 
measuring blood levels of spiramycin and the extent of 
variation in blood levels between women (Gratzl et al. 
1999). More importantly, pyrimethamine-sulphonamide 
combinations  have  two  major  disadvantages.  Firstly, 
there is clear evidence from cohort studies that adverse 
drug effects are more common and more serious with 
pyrimethamine-sulphonamide  combinations  than  with 
spiramycin during pregnancy (Daveluy et al. 2005). Sec-
ondly, if these treatments are equivalent, there may be 
no need to expose women to the risks of fetal loss and 
costs of prenatal diagnosis as there is no need to change 
treatment to a pyrimethamine-sulphonamide combina-
tion (Thalib et al. 2005).
Another important clinical question is whether it is 
necessary to continue treatment throughout pregnancy. 
There has been a long-standing belief that mother to 
child transmission may be delayed over weeks or months. 
Clinical studies comparing the timing of amniocentesis 
after maternal seroconversion provide no evidence to 
support this belief and the strong relationship between 
maternal seroconversion and congenital infection sug-
gests that mother to child transmission occurs very early 
after  infection  (Thalib  et  al.  2005,  SYROCOT  Study 
Group 2007). So why continue treatment if prenatal di-
agnosis is negative? The reason often given is the poor 
sensitivity of prenatal diagnosis based on PCR. Howev-
er, clinicians and the women themselves might want to 
reflect on the risks involved. For a woman who serocon-
verts at 12 weeks of gestation who has a negative PCR 
test (sensitivity around 33%), her risk of mother to child 
transmission is at the most, 3% (Thalib et al. 2005). If 
treatment is effective, the risk will be even lower, as she 
would have been treated prior to prenatal diagnosis. 
Prenatal treatment: what are the research priorities?
The systematic review concluded that only a large 
randomised controlled clinical trial that compared pre-
natal treatment with no treatment or placebo, could pro-
vide clinicians and patents with valid evidence of the po-
tential benefit of prenatal treatment (SYROCOT Study 
Group  2007).  Randomisation  of  individual  women  is 
the only way to minimise problems of selection bias re-
lated to disease severity and confounding due to timing 
of maternal seroconversion. From a policy perspective, 
randomised controlled trials need to compare treatment 
TABLE
Summary of evidence for different treatment comparison and outcomes
  Any treatment   Early  P&S  Long
  vs   vs  vs  vs
  none  delayed  spiramycin alone  short treatment
Prenatal       
   Mother-child transmission  no eb  weak eb  no eb  ns
   Brain lesions  no eb  weak eb  no eb  ns
   Retinochoroiditis   no eb  no eb  no eb  ns
   Serious neuro impairment  in progress  ns  ns  ns
Postnatal      ns  ns
   Retinochoroiditis after birth  no eb limited  no eb limited  ns  ns
no eb: no evidence of benefit. Cohort studies have been done, but show no evidence for differences in outcomes at the 5% level 
of significance; no eb limited: studies have addressed this comparison, but they had limited power to detect a difference; ns: 
no studies; weak eb: some studies have found a difference of borderline significance at the 5% level. Differences may be due to 
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with no treatment, or better still, with placebo. Only 
then can policy makers know whether the more than 
100 million Euros spent each year on prenatal screening 
in France are cost effective (Gilbert & Peckham 2002). 
Such trials need to be carefully designed given the ethi-
cal imperative for benefit once screening has identified 
a problem that the woman would not otherwise have 
known about. Trials that aim to minimise harms of treat-
ment are also urgently needed. These may take the form 
of ‘head to head’ comparisons of different treatments 
(e.g.:  pyrimethamine-sulphonamide  vs  spiramycin)  or 
withdrawal trials [e.g.: treatment throughout pregnancy 
compared with short course treatment for women with 
a negative prenatal diagnosis (Table)]. Such trials would 
aim to establish whether outcomes (e.g.: transmission or 
clinical manifestations) are equivalent for the compari-
son groups. If they are, rational clinical practice would 
favour the least harmful option. These recommendations 
for progressing understanding of treatment effectiveness 
apply regardless of setting or parasite strain. 
The systematic review stated very clearly that fur-
ther evidence from cohort studies would be unlikely to 
change what we already know about treatment effective-
ness (SYROCOT Study Group 2007). This is true. But 
cohort studies remain vital to determine prognosis, par-
ticularly the risk and severity of disability later in child-
hood. Nowhere are such prognostic studies needed more 
than in South America, where the disease is a major 
public health problem. Furthermore, such cohort studies 
should be multicentre, using the same protocol so that 
outcomes  are  comparable,  and  conducted  in  different 
regions depending on which strains predominate. Tried 
and tested follow up protocols are available for research-
ers from the Brasil-EMSCOT study (Gilbert et al. 2008). 
These would allow results to be compared with previ-
ous cohorts in Brazil and Europe. Even less attention has 
been given to researching the burden and clinical course 
of  congenital  toxoplasmosis  in  Africa,  despite  some 
evidence of severe disease, particularly in West Africa 
(Ronday et al. 1996, Gilbert et al. 1999). 
Postnatal treatment: what do we know already?
Postnatal treatment is usually given to infected infants 
as prophylactic treatment to reduce the risk of retinocho-
roiditis developing after birth. The rationale for prophy-
laxis early in infancy is that cyst density diminishes with 
time after infection and cyst breakdown occurs more fre-
quently with less mature immunity. Conversely, we could 
expect prophylaxis to be less effective as the child’s own 
immune response matures. A further reason is that the 
alternative option, symptomatic treatment in response to 
ocular symptoms, only becomes feasible as children grow 
older and are able to express symptoms. 
The effect of postnatal treatment has not been ad-
dressed by any concurrent comparative studies because 
once a baby is identified as infected, most clinicians 
have felt obliged to treat (Freeman et al. 2008). One ex-
ception was a Dutch cohort of 12 infected infants, half 
of whom were treated prenatally. Paediatricians could 
not be persuaded to treat postnatally, because infants 
had no or only mild signs, and because of the lack of 
evidence that benefits justified a burdensome and po-
tentially harmful treatment regimen (Gilbert et al. 2001). 
A comparison of the Dutch cohort with other cohorts in 
which children were treated postnatally, or prenatally 
and postnatally, showed no significant difference in the 
risk of retinochoroiditis by three years of age (Gilbert 
et al. 2001).  However, the power to detect an effect was 
limited. In the EMSCOT cohort, we found no evidence 
for an effect of early versus late postnatal treatment on 
newly occurring retinochoroiditis after an initial nega-
tive  examination  (Gilbert  et  al.  2001).  However,  the 
power to detect an effect was low. Differences reported 
between referred case series of children in the USA in 
the  1950s  (untreated)  and  more  recently  (treated)  are 
uninterpretable (McAuley et al. 1994). Postnatal treat-
ment is only one of many explanations for the difference 
in outcomes, another being referral bias favouring less 
severely infected children in the more recent cohort. In 
summary, it is hard to deduce anything about the effec-
tiveness of postnatal treatment from cohort studies to-
date. Randomised controlled trials are urgently needed 
to evaluate prophylactic treatment. 
Postnatal treatment: what are the research priorities?
To design trials to evaluate postnatal treatment, we 
need to be clear about the underlying prognosis for new 
retinochoroidal lesions after birth and the likely magni-
tude of the treatment effect. We know from the lack of 
evidence for a significant effect of prenatal treatment on 
retinochoroidal lesions that any effect of postnatal treat-
ment is likely to be small (Binquet et al. 2003, SYRO-
COT Study Group 2007, Freeman et al. 2008). To ex-
pect postnatal treatment to halve the risk of new lesions 
(relative risk of 0.5) would be extremely optimistic, and 
a 20% reduction might be more realistic (relative risk 
0.8).  Secondly,  we  know  from  European  cohorts  that 
84% of infected children identified by screening and 
with no retinochoroiditis or other clinical manifestations 
detected at postnatal examinations before four months 
of age have a low risk (8%; 95%CI: 4-12%) of develop-
ing retinochoroiditis by four years of age (Freeman et al. 
2008). Their risk of bilateral visual impairment will be 
much less than the 9% estimated for all children with 
retinochoroiditis as this group of children had no lesions 
at birth (Tan et al. 2007). These data are from treated 
children, but the risk for untreated children will not be 
much higher given the small expected treatment effect. 
The implications are that for five out of six infected 
infants identified by European screening programmes, 
the harms of postnatal treatment for one year could read-
ily outweigh any benefits. So what should clinicians and 
researchers do? Firstly, there is an ethical imperative to 
share this information with parents when making deci-
sions about postnatal treatment and follow up. Secondly, 
clinicians should consider not treating and not following 
up these children. Evidence is needed of the effectiveness 
of repeated routine ophthalmic examinations throughout 
childhood for children with normal ophthalmoscopy af-
ter birth given their low risk of retinochoroiditis. Instead, 
clinicians could advise parents to bring the child for as-
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ensure that routine school vision screening is undertaken 
at 3-4 years old. In the Danish cohort, ophthalmologists 
could not be persuaded of the benefits of annual oph-
thalmoscopy examinations (E Petersen, personal com-
munication), whereas in some centres examinations are 
repeated at six monthly intervals (Freeman et al. 2008). 
We previously reported that at 3-4 years, infected and 
uninfected children born to toxoplasma infected moth-
ers had no detectable differences in a range of develop-
mental outcomes, but parents of infected children were 
significantly more anxious (Freeman et al. 2005). Part of 
this anxiety may be attributable to concerns about vision 
loss in their child, a fear that is reinforced by repeat-
ed  examinations.  Thirdly,  these  alternative  strategies 
should be evaluated in a randomised controlled trial, al-
though the challenges to doing so are considerable. The 
trial would need to be very large, because the expected 
difference is small, and follow up would need to be for 
many years. A further problem is that lack of blinding 
of treatment allocation and the need for intermittent as-
sessments in both trial arms over a long period would 
make contamination between trial arms quite likely. In 
other words, children allocated to treatment might well 
stop taking it, and those allocated to no treatment might 
be more ready to start treatment for any small peripheral 
lesion found on routine examination. A fourth option for 
neonatal screening centres is to stop screening. After 
starting the programme in 1992, the Danish National 
Screening Programme took the decision to stop screen-
ing in August 2007 because of the low burden of dis-
ease and lack of evidence that treatment is effective (E 
Petersen, personal communication). Neonatal screening 
programmes in Massachusetts and Ireland, both areas 
where the type II genotype of the parasite predominates, 
should similarly consider whether ongoing screening is 
justified (Gilbert & Dezateux 2006). 
The research priority for children with clinical signs 
after birth (16% of infected children in European co-
horts) is for treatment withdrawal or harm limitation tri-
als. This would mean randomising infected children to 
12 month or three months of treatment or to less toxic 
treatment  regimens  compared  with  the  standard  py-
rimethamine-sulphonamide combination. 
The need for trials of different treatment options is 
even more urgent for South America where the large ma-
jority of infected children identified by screening have 
clinical signs detected after birth. In addition, their risk 
of subsequent retinochoroiditis is very much higher than 
for children in Europe and the risk of visual impairment 
given a lesion is higher. The impact of visual impair-
ment on quality of life and economic sustainability in 
adulthood is also likely to be worse in less developed 
settings. On the other hand, the potential harms of neu-
tropenia due to treatment, and the burden of treatment 
and complying with follow up, may also be higher in less 
developed settings. 
While Europe and North America argue the ethics 
and cost effectiveness of marginal benefits of screening 
programmes,  evidence  is  emerging  from  high  quality, 
population-based studies in South America that congeni-
tal toxoplasmosis is a major public health problem (Bahia-
Oliveira et al. 2001, Neto et al. 2004,  Portela et al. 2004, 
Gomez-Marin et al. 2007, Lago et al. 2007, Andrade et 
al. 2008, Gilbert et al. 2008). Moreover, these clinician 
researchers are demonstrating that they can implement 
neonatal screening and follow up programmes to the high 
standards of quality that need to be reached before screen-
ing can be considered a feasible option. 
The onus is now on the research community and re-
search funders. In South America congenital toxoplas-
mosis is an important public health problem that prenatal 
or neonatal screening, or both, may help to ameliorate. 
Policy makers need to know whether treatment works 
and whether screening is cost effective. This requires 
coordinated, high quality, multicentre randomised con-
trolled trials, linked to ongoing cohort studies of children 
identified by screening. Researchers in South America 
have shown that the skills and infrastructure are there to 
answer these questions in the next 10 years rather than 
the next 100. What is needed is prioritisation from inter-
national funders and fruitful collaboration. 
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